SOLESENCE, INC. SLSN
March 7, 2025, Nanophase Technologies Corporation announced its rebranding as Solésence, Inc. ("Solésence,"
"Company," "we," "our," or "us"), marking a new chapter in its commitment to skin
health innovation and consumer products across beauty, health, and wellness categories. Our corporate website has transitioned
to solesence.com and investor relations information, including historical Nanophase financials and disclosures, is available at
Last close
0.85
2026-09-04
Market cap
$60.0M
2026-06-30 share count
52-week range
0.61 - 4.55
Valuation FY2025 figures against the last close
P/S1.0x
P/E42.5x
P/FCF—
EV/EBITDA24.3x
Dividend yield—
Diluted EPS0.02
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.1M | $52.3M | $37.3M | $37.3M | $29.5M | $17.1M | $12.5M | $14.2M | $12.5M | $10.8M |
| Cost of revenue | $46.0M | $36.2M | $29.5M | $29.0M | $20.8M | $11.1M | $9.9M | $10.9M | $8.6M | $7.5M |
| Gross profit | $16.1M | $16.2M | $7.8M | $8.4M | $8.7M | $6.0M | $2.6M | $3.3M | $3.9M | $3.2M |
| R&D | $4.1M | $3.8M | $3.8M | $3.0M | $2.2M | $1.6M | $1.9M | $2.1M | $1.7M | $1.6M |
| SG&A | $10.4M | $7.2M | $7.5M | $7.6M | $3.9M | $2.9M | $3.5M | $3.3M | $2.9M | $3.0M |
| Total operating expenses | $60.3M | $48.1M | $41.7M | — | — | — | — | — | — | — |
| Operating income | $1.6M | $5.1M | -$3.5M | -$2.3M | $2.6M | $1.5M | -$2.8M | -$2.0M | -$772.0K | -$1.3M |
| Interest expense | — | $670.0K | $838.0K | $382.0K | $1.2M | $496.0K | $210.0K | $58.0K | $34.0K | $15.0K |
| Pre-tax income | $1.9M | $4.5M | -$4.4M | -$2.6M | $2.4M | $989.0K | -$3.0M | -$2.1M | -$789.0K | -$1.3M |
| Income tax | $73.0K | $227.0K | $6.0K | $17.0K | $37.0K | — | — | $0 | $0 | — |
| Net income | $1.8M | $4.2M | -$4.4M | -$2.6M | $2.3M | $989.0K | -$3.0M | -$2.1M | -$789.0K | -$1.3M |
| EPS, basic | 0.03 | 0.07 | -0.09 | -0.05 | 0.05 | 0.03 | -0.08 | — | — | — |
| EPS, diluted | 0.02 | 0.07 | -0.09 | -0.05 | 0.05 | 0.03 | -0.08 | -0.06 | -0.03 | -0.04 |
| Shares, diluted (wtd. avg.) | $72.6M | $65.0M | $49.6M | $49.1M | $47.0M | $38.5M | $36.6M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $1.4M | $1.7M | $2.2M | $657.0K | $957.0K | $1.2M | $1.3M | $2.0M | $1.8M |
| Receivables | $6.8M | $4.9M | $3.5M | $4.7M | $3.9M | $2.9M | $970.0K | $829.0K | $1.1M | $434.0K |
| Inventory | $18.5M | $20.3M | $10.0M | $8.8M | $6.1M | $4.3M | $2.6M | $2.2M | $1.4M | $772.0K |
| Total current assets | $28.8M | $29.3M | $16.3M | $16.6M | $11.6M | $8.8M | $5.0M | $4.7M | $4.6M | $3.4M |
| Property, plant and equipment | $14.3M | $12.7M | $8.7M | $7.9M | $4.7M | $2.9M | $2.3M | $1.9M | $1.6M | $1.4M |
| Total assets | $50.1M | $50.0M | $32.9M | $33.6M | $28.4M | $13.5M | $9.4M | $6.6M | $6.3M | $4.8M |
| Accounts payable | $4.1M | $9.1M | $6.3M | $6.4M | $3.6M | $2.1M | $1.7M | $1.6M | $1.0M | $669.0K |
| Short-term debt | — | — | — | — | — | $500.0K | $500.0K | — | — | — |
| Total current liabilities | $13.9M | $25.8M | $15.6M | $13.8M | $7.3M | $6.8M | $4.4M | $3.6M | $2.0M | $1.3M |
| Long-term debt | — | — | — | $1.0M | $1.0M | $952.0K | — | — | — | — |
| Retained earnings | -$98.6M | -$100.4M | -$104.7M | -$100.1M | -$97.4M | -$99.8M | -$100.8M | -$97.8M | -$95.7M | -$94.9M |
| Total equity | $17.6M | $14.9M | $1.9M | $5.6M | $7.5M | $2.7M | $1.5M | $1.4M | $3.2M | $2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.6M | $2.0M | -$2.0M | -$1.6M | $2.3M | -$2.1M | -$2.8M | -$1.3M | -$960.0K | -$241.0K |
| Depreciation and amortisation | $897.0K | $928.0K | $918.0K | $567.0K | $454.0K | $358.0K | $315.0K | $322.0K | $344.0K | $610.0K |
| Stock-based compensation | $575.0K | $725.0K | $773.0K | $625.0K | $160.0K | $195.0K | $242.0K | $204.0K | $183.0K | $207.0K |
| Capital expenditure | — | $4.6M | $1.1M | $2.8M | $1.9M | $878.0K | $740.0K | $160.0K | $209.0K | $128.0K |
| Investing cash flow | -$2.1M | -$4.6M | -$1.1M | -$2.8M | -$1.9M | -$878.0K | -$740.0K | -$160.0K | -$72.0K | -$165.0K |
| Financing cash flow | $10.6M | $2.3M | $2.6M | $6.0M | -$747.0K | $2.7M | $3.4M | $892.0K | $1.2M | $910.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001999371-26-007345.
Others in SIC 2844
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CL | COLGATE PALMOLIVE CO | $70.77B | 33.8x | 1.4% |
| EL | ESTEE LAUDER COMPANIES INC | $37.63B | 207.7x | 5.0% |
| KVUE | Kenvue Inc. | $36.00B | 24.7x | -2.1% |
| ELF | e.l.f. Beauty, Inc. | $6.47B | 249.2x | 24.6% |
| IPAR | INTERPARFUMS INC | $3.74B | 22.3x | 2.5% |
| COTY | COTY INC. | $2.58B | — | -1.5% |
| EPC | EDGEWELL PERSONAL CARE Co | $1.33B | 54.5x | -1.3% |
| WALD | Waldencast plc | $156.3M | — | -0.7% |